key: cord-0721142-bsvyr1yh authors: Lin, Chen; Arevalo, Yurany A.; Nanavati, Hely D.; Lin, Diana M. title: Racial differences and an increased systemic inflammatory response are seen in patients with COVID-19 and ischemic stroke date: 2020-09-01 journal: Brain Behav Immun Health DOI: 10.1016/j.bbih.2020.100137 sha: e0c5de38484742e3431f64c8df09b69a9bcb213f doc_id: 721142 cord_uid: bsvyr1yh OBJECTIVE: To describe the difference in clinical presentation, including race, of ischemic stroke between patients with and without novel coronavirus disease 2019 (COVID-19), and the association of inflammatory response with stroke severity. METHODS: This is a retrospective, observational, cross-sectional study of patients (n=60) admitted with ischemic stroke between late March and early May 2020. All patients were tested for COVID-19 during admission. Demographic, clinical, and laboratory data was collected through electronic medical record review. Descriptive statistics was performed to observe the differences between stroke patients with and without COVID-19. RESULTS: 60 hospitalized patients with acute ischemic stroke were included in the analysis. Nine were positive for COVID-19. African-Americans comprised of 55.6% of those that had COVID-19 and stroke and 37.7% of those with only stroke. Stroke patients with COVID-19 had a significantly higher NIHSS [18.4 (8.8)] and neutrophil-to-lymphocyte ratio (NLR) [7.3 (4.2) vs 3.8 (2.8); P=0.0137] than those without. Those with COVID-19 also had a significantly higher mortality rate (44.4% vs. 7.6%; p<0.001). CONCLUSION: We observed a cohort of patients, including a large proportion of African-Americans, who developed ischemic stroke with or without COVID-19. An exaggerated inflammatory response, as indicated by NLR, likely plays a role in stroke severity among COVID-19 patients that concurrently develop ischemic stroke. In early March 2020, the World Health Organization declared the outbreak caused by the novel coronavirus disease 2019 (COVID-19) as a public health emergency of international concern. 1 Since then, our knowledge of the clinical phenotype has evolved considerably. Symptoms of COVID-19 go beyond just lung involvement to potentially affecting all organ systems. 2 More literature have reported COVID-19 impacting the neurologic system, specifically with cerebrovascular disease. 1, 3, 4 However, most reports of COVID-19's association with stroke have focused on either how our systems of care have changed 5, 6 or are limited case series reports. 1, 7 One proposed etiology has been an exaggerated systemic inflammation response to the virus can lead to ischemic stroke, but prior studies have been limited. 8 The neutrophil to lymphocyte ratio (NLR) is an established inflammation marker of the systemic inflammatory response and is easily calculated from routine blood work by dividing absolute neutrophil count by absolute lymphocyte count. 9, 10 Patients with more severe COVID-19 have been shown to have higher NLR, indicating an enhanced inflammatory process that might not be detected with other inflammatory markers. 8, 9, 11 Importantly, racial differences have impacted outcomes of patients with COVID-19. 12 In this study, we describe the clinical differences, including race, between ischemic stroke patients with and without COVID-19 and laboratory findings including NLR. Methods This is an observational, cross-sectional study of patients with confirmed acute ischemic stroke between late March to early May 2020 at a single-center urban academic referral hospital in the Southern United States. The hospital receives patients from multiple neighboring Southern states. Data was obtained using the center's registry of patients admitted with acute ischemic stroke. The registry received Institutional Review Boards (IRB) approval and followed the standards to protect patients' safety and privacy while gathering clinical information. Patients (≥18 years) presenting to the center with imaging-verified ischemic stroke during the study period were identified. Electronic medical records were abstracted to confirm stroke cases, and to collect information on: Demographics (age, gender, race), clinical variables (co-existing conditions), laboratory data (complete blood count, blood chemistry, and coagulation tests at admission), and prognostic outcomes (mortality, length of hospital stay, discharge disposition). NLR served as an index of systemic inflammatory response. 8 Upon admission, all patients in our cohort were tested for COVID-19 infection similarly to other reported protocols. 1 Testing for COVID-19 were performed in accordance with standards established by the World Health Organization using reversetranscriptase polymerase chain reaction from nasopharyngeal swab samples. We We calculated descriptive statistics using Wilcoxon two-sample test and Fisher's exact test for continuous and categorical variables, respectively. All analysis was performed using SAS version 9.4 (Cary, USA). A total of 60 hospitalized patients with acute ischemic stroke were included in the analysis, of whom nine were positive for COVID-19 infection. Average age of infected patients was 58.2 ± 18.3 years, three were male, and five were African American. At the time of admission, they presented with a more severe neurological deficit as indicated by a higher NIHSS 18.4 ± 8.8 (p=0.04). Otherwise, past medical history and stroke subtypes were similar between groups. Table 1 reports demographics, clinical variables, laboratory findings, and prognostic outcomes. J o u r n a l P r e -p r o o f Prognostic outcomes: Stroke patients with COVID-19 had a significantly higher mortality rate (44.4% vs. 7.6%; p<0.001) compared to those without COVID-19. The average length of hospital stay in discharged patients was longer for stroke patients with COVID-19 than those without, but the difference was not clinically significant. We report important clinical and laboratory differences in ischemic stroke patients with and without COVID-19. To our knowledge, two prior studies have compared these two populations, neither of which addressed racial differences or NLR differences between groups. 3, 13 We report the first experience within the "Stroke Belt" of the Southern United States, which has the highest proportion of African-American stroke patients. 14 Our cohort had a higher proportion of African-American patients with COVID-19 and stroke than the New York cohort (55.6% vs 15.6%). 3 This racial disparity could be due to a higher proportion of African American population in the Southeast region compared to other parts of the country. Additionally, the New York cohort did not report their number of African-Americans with stroke who did not have COVID. The Southern United States has disproportionately higher rates of stroke mortality than the rest of the country. 14 As COVID-19 has disproportionately burdened African-American communities, 15 disparities are likely to widen with other medical conditions 16 as well that disproportionately affect this community, such as stroke. 17 Additionally, experiences with racial discrimination were associated with elevated cytokine levels in certain African-American groups. 18 These findings offer an important opportunity to focus education and public health resources on vulnerable populations. Some studies have suggested the coagulopathy from COVID-19 is caused by a precursor state to disseminated intravascular coagulation. 19 In our study, we had a small but significant increase in coagulation factors in COVID-19 positive stroke patients compared to those without COVID-19. However, coagulation factors were not independently associated with stroke severity in our study. In contrast, we saw a significantly higher NLR in COVID-19 patients. NLR is a well-studied serum biomarker for systemic inflammation in COVID-19. 8, 10, 20 The components of the NLR are routinely collected in clinical practice, unlike other systemic inflammatory markers like C-reactive protein and cytokine levels. 9 As part of the complete blood count with differential, the neutrophil count and the lymphocyte count, are already obtained and the ratio can be easily calculated. This would make NLR a cost-effective marker in helping assess disease severity and predict complications. 9 Interestingly, in our patients with stroke and COVID-19, the neutrophil and lymphocyte levels were only borderline high and low, respectively. Yet, the NLR was almost twice as high as patients without COVID-19. This potentially indicates that the patients. 8 Notably, mean NLR was 7.3 in our study. Increased NLR has also been associated with COVID-19 disease severity, refractory disease, and even an independent factor for mortality. 11 Our study is the first study to associate the NLR in patients with COVID-19 and ischemic stroke and stroke severity. to an excessive production of cytokines or "cytokine storm." 19, 21 Neutrophils triggered by viral-related cytokines cause tissue damage by release of reactive oxygen species, and inhibit the cytotoxic T-cell response needed to fight viral infection. 8 Proinflammatory cytokines are known to be increased in COVID-19 patients and associated with disease severity. 19, 22 Subsequent vascular leakage and interstitial edema damage tissues including myocardium and blood vessels. 21 A recent study found T-cells were reduced in COVID-19 patients requiring critical care, and these reductions were associated with higher cytokine levels. The authors suggested T-cells were initially hyperactivated and subsequently exhausted in the infection process, impairing anti-viral immunity. 23 Perhaps the lower circulating lymphocyte counts in our COVID-19 patient cohort was due to reduced T-cells. T-cell lymphocytes are needed to dampen an overactive innate immune response, and subsequent increase of these lymphocytes are seen in disease recovery. 22 Prior studies of COVID-19 patients found increased neutrophils are associated with a higher risk of acute respiratory distress syndrome, while lymphopenia has been associated with worse outcomes, increased need for critical care, and increased mortality. 24 Medications that can block the systemic J o u r n a l P r e -p r o o f inflammatory response such as Dexamethasone, a corticosteroid, have had early reports that suggest improved outcomes due to its ability to suppress neutrophils. 25 African-Americans have known genetic variations associated with inflammation measured using the NLR and increased risk of cardiovascular disease and stroke. 26, 27 In these populations who receive medications like dexamethasone, it will be important to monitor the differences in their medications effects. Our study has several limitations. First, this was a retrospective, observational single-center study with a small sample size, which limited our ability to perform multivariable statistical analysis. Secondly, even though overall our cohort had a large proportion of African American population, within the COVID-19 group, the absolute difference in the numbers of African American patients versus other race was one. Therefore, the results of this report should be interpreted with caution. Third, not all patients had the same completeness of laboratory data and so some comparisons could not be made. Fourth, we do not have all prognostic outcomes since some patients were still admitted and receiving clinical care. Finally, we did not study hemorrhagic stroke, which warrants further investigation. We observed a cohort of patients including a large proportion of African-American population, who developed ischemic stroke with or without COVID-19. Those with COVID-19 and ischemic stroke had higher stroke severity and increased mortality. We also found that an increased NLR among stroke patients with COVID-19 indicates a more severe systemic inflammatory response that impacts clinical characteristics and warrants further investigation. COVID-19 presenting as stroke Clinical features of patients infected with 2019 novel coronavirus in Wuhan SARS-CoV-2 and Stroke in a New York Healthcare System COVID-19-Related Stroke Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic Collateral Effect of Covid-19 on Stroke Evaluation in the United States Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 Ethnic disparities in COVID-19 mortality: are comorbidities to blame? Lancet Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke Regional differences in African Americans' high risk for stroke: the remarkable burden of stroke for Southern African Americans Characteristics Associated with Hospitalization Among Patients with COVID-19 Increased cardiovascular mortality in African Americans with COVID-19 The impact of COVID-19 on African American communities in the United States Racial discrimination predicts greater systemic inflammation in pregnant African American women Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019 Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) Hematological findings and complications of COVID-19 Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv Mediation Effect of Neutrophil Lymphocyte Ratio on Cardiometabolic Risk Factors and Cardiovascular Events Association of Neutrophil-to-Lymphocyte Ratio With Mortality and Cardiovascular Disease in the Jackson Heart Study and Modification by the Duffy Antigen Variant J o u r n a l P r e -p r o o f